Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 5/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 3/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8974027 | 0.79 | SMPD1 (0.58) | SMPD1PDE4BFPR2PDE4APDE4C | |
| SCHEMBL3374953 | 0.79 | PDE4B (0.48) | PDE4BFPR2PDE4APDE4CPDE4D | |
| SCHEMBL3377680 | 0.78 | PDE4B (0.38) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL8975125 | 0.73 | THRA (0.53) | SMPD1FPR2CNR2 | |
| SCHEMBL2856448 | 0.70 | PTPN11 (0.55) | SMPD1FPR2 | |
| SCHEMBL28319408 | 0.70 | PTPN11 (0.55) | SMPD1FPR2 | |
| SCHEMBL1776071 | 0.70 | PTPN11 (0.55) | SMPD1FPR2 | |
| SCHEMBL13957128 | 0.70 | PTPN11 (0.55) | SMPD1FPR2 | |
| SCHEMBL27552799 | 0.68 | SMPD1 (0.54) | SMPD1PDE4BCNR2PDE4APDE4C | |
| SCHEMBL22502366 | 0.68 | GAA (0.57) | SMPD1PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324091-A1 | Pyrazolone Derivative | KOWA COMPANY, LTD. (JP) | 2010-12-23 | — | — | US | disclosed |
| EP-2172458-A1 | PYRAZOLONE DERIVATIVE | Kowa Company, Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324091-A1 | Pyrazolone Derivative | SERPINE1, SERPINC1, TFPI | SMPD1 1889/4885PDE4B 1700/4885FPR2 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.